BNP Paribas Exane Downgrades Organon & Co. (OGN) to Neutral Post Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Sun Pharma signs Definitive Agreement to Acquire Organon
April 26, 2026 7:51 PM EDTOrganon stockholders to receive US$ 14.00 per share in cash
The deal values Organon at EV of US$ 11.75 billion
Combined Business leverages complementary portfolios and global scale for sustained longterm value creation
MUMBAI, India & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, Sun Pharma) and Organon & Co. (NYSE: OGN) (Organon) today... More
